» Articles » PMID: 38553649

A Whole Food, Plant-based Randomized Controlled Trial in Metastatic Breast Cancer: Feasibility, Nutrient, and Patient-reported Outcomes

Abstract

Purpose: Quality of life (QOL) is among the most important outcomes for women with metastatic breast cancer (MBC), and it predicts survival. QOL is negatively impacted by cognitive impairment, fatigue, and weight gain. We assessed whether a whole food, plant-based (WFPB) diet-promoting weight loss is feasible and might improve QOL.

Methods: Women with MBC on stable systemic treatments were randomized 2:1 to 1) WFPB dietary intervention (n = 21) or 2) usual care (n = 11) for 8 weeks. Participants attended weekly education visits and consumed an ad libitum WFPB diet (3 prepared meals/day provided). Patient-reported outcomes and 3-day food records were assessed at baseline and 8 weeks. The effects of WFPB diet on changes in outcomes were assessed by analysis of covariance model controlling for baseline.

Results: 20 intervention and 10 control participants completed the trial. Intervention participants were highly adherent to the WFPB diet (94.3 % total calories on-plan). Intervention group nutrient intakes changed significantly including dietary fat (35.8 % to 20.4 % percent calories from fat, p < 0.001) and fiber content (12.7 to 30.8 g fiber/1000 kcal, p < 0.001). Perceived cognitive function (FACT-Cog total + 16.1; 95 % confidence interval [CI] = 0.8-31.7; p = 0.040) and emotional well-being (FACT-B emotional well-being subscale + 2.3; CI = 0.5-4.1; p = 0.016) improved in the WFPB versus the control group. Fatigue, measured by the BFI, improved within the WFPB group for fatigue severity (M = 4.7 ± 2.5[SD] to 3.7 ± 2.3, p = 0.047) and fatigue at its worst (5.8 ± 2.8 to 4.4 ± 2.4, p = 0.011).

Conclusions: Significant dietary changes in this population are feasible and may improve QOL by improving treatment-related symptoms. Additional study is warranted.

Trial Registration: ClinicalTrials.gov identifier: NCT03045289. Registered 7 February 2017.

Citing Articles

A whole food, plant-based diet reduces amino acid levels in patients with metastatic breast cancer.

Scales T, Smith B, Blanchard L, Wixom N, Tuttle E, Altman B Cancer Metab. 2024; 12(1):38.

PMID: 39702320 PMC: 11657127. DOI: 10.1186/s40170-024-00368-w.


A cross-sectional survey exploring knowledge, beliefs and barriers to whole food plant-based diets amongst registered dietitians in the United Kingdom and Ireland.

Metoudi M, Bauer A, Haffner T, Kassam S J Hum Nutr Diet. 2024; 38(1):e13386.

PMID: 39491806 PMC: 11589407. DOI: 10.1111/jhn.13386.


A whole food, plant-based diet reduces amino acid levels in patients with metastatic breast cancer.

Scales T, Smith B, Blanchard L, Wixom N, Tuttle E, Altman B medRxiv. 2024; .

PMID: 39417128 PMC: 11483017. DOI: 10.1101/2024.10.09.24315165.


Changes in the consumption of isoflavones, omega-6, and omega-3 fatty acids in women with metastatic breast cancer adopting a whole-food, plant-based diet: post-hoc analysis of nutrient intake data from an 8-week randomized controlled trial.

Lee J, Campbell E, Culakova E, Blanchard L, Wixom N, Peppone L Front Nutr. 2024; 11:1338392.

PMID: 38577156 PMC: 10991800. DOI: 10.3389/fnut.2024.1338392.


A whole-food, plant-based randomized controlled trial in metastatic breast cancer: weight, cardiometabolic, and hormonal outcomes.

Campbell T, Campbell E, Culakova E, Blanchard L, Wixom N, Guido J Breast Cancer Res Treat. 2024; 205(2):257-266.

PMID: 38446316 PMC: 11101531. DOI: 10.1007/s10549-024-07266-1.

References
1.
Sheean P, Kabir C, Rao R, Hoskins K, Stolley M . Exploring Diet, Physical Activity, and Quality of Life in Females with Metastatic Breast Cancer: A Pilot Study to Support Future Intervention. J Acad Nutr Diet. 2015; 115(10):1690-8. PMC: 4584161. DOI: 10.1016/j.jand.2015.03.017. View

2.
Hiensch A, Monninkhof E, Schmidt M, Zopf E, Bolam K, Aaronson N . Design of a multinational randomized controlled trial to assess the effects of structured and individualized exercise in patients with metastatic breast cancer on fatigue and quality of life: the EFFECT study. Trials. 2022; 23(1):610. PMC: 9335464. DOI: 10.1186/s13063-022-06556-7. View

3.
Cheung Y, Foo Y, Shwe M, Tan Y, Fan G, Yong W . Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: cognitive function (FACT-Cog) in breast cancer patients. J Clin Epidemiol. 2014; 67(7):811-20. DOI: 10.1016/j.jclinepi.2013.12.011. View

4.
Klemp J, Myers J, Fabian C, Kimler B, Khan Q, Sereika S . Cognitive functioning and quality of life following chemotherapy in pre- and peri-menopausal women with breast cancer. Support Care Cancer. 2017; 26(2):575-583. PMC: 5754254. DOI: 10.1007/s00520-017-3869-3. View

5.
Mortensen G, Madsen I, Krogsgaard R, Ejlertsen B . Quality of life and care needs in women with estrogen positive metastatic breast cancer: a qualitative study. Acta Oncol. 2017; 57(1):146-151. DOI: 10.1080/0284186X.2017.1406141. View